ArticleCancer cell international2025
Environmental interpretation of the impact of vehicle emissions on prostate cancer progression.
Article in Cancer cell international, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
objectiveVehicle emissions (VEs) are considered important causes of air pollution in cities. This study aims to analyze the role of VEs in the progression of prostate cancer (PCa).
methodsWe used the CTD database to obtain genes associated with VEs in prostate cancer to explore the associations between VEs and prostate cancer. LASSO regression analysis was subsequently used to construct a novel VEs-related progression model in the TCGA and GEO databases. Differences in the progression-free interval (PFI), clinical characteristics and immune characteristics were compared among patients with different VEs score. Finally, we confirmed that the changes of DNMT3B after VEs mediation and that DNMT3B promoted the progression of prostate cancer by preliminary experiments.
resultsThe analysis of VEs-enriched diseases revealed the most significant enrichment in the prostate cancer pathway. The GO enrichment analysis observed that VEs affected multiple signaling pathways and biological processes in PCa. On the basis of VEs-associated genes, we relied on the VEs scoring model to accurately evaluate the PFI (p < 0.05). In patients with high VEs scores, tumor mutation burden (TMB) (R = 0.29, p < 0.001) and the cytolytic activity (CYT) (R = 0.161, p < 0.001) scores were increased, as was the expression of immunosuppressive ligands. Functional experiments showed that knockdown of DNMT3B inhibited the proliferation, colony formation and migration of prostate cancer cells in vitro. In addition, we found that DNMT3B expression was significantly increased in tumor cells after VEs treatment.
conclusionsThis study presents unique opinions into the impact of VEs on prostate cancer progression and highlights the need for more in-depth exploration of the mechanistic link between VEs and prostate cancer progression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.